title: Sodium valproate-induced Fanconi type proximal renal tubular acidosis.
abstract: We present a case series of three patients with sodium valproate-induced Fanconi's syndrome, with ages ranging from 5 years to 12 years. The most important diagnostic features of this syndrome include hypophosphataemia, glycosuria and proteinuria, which are also noted in our series. Furthermore, also added is that clinical fractures representing an underlying osteopaenia may provide an opportunity for early intervention as it raises the suspicion of Fanconi's syndrome. Previous case reports suggest there is a subpopulation of individuals who are at risk of developing this condition. These individuals share similar characteristics, including being non-ambulatory, developmentally delayed and/or tube fed. Withdrawing sodium valproate therapy is the ultimate treatment for valproate-induced Fanconi's syndrome and from previous case series, normalised renal function occurs in approximately 6 months. Often, supplement support is also required for deranged electrolyte balance.
authors.affiliation: University of Leeds Teaching Hospitals, Leeds, UK.
authors.forename: Mark
authors.initials: M
authors.lastname: Knights
authors.affiliation: Sheffield Children's Hospital, Sheffield, UK.
authors.forename: Tina
authors.initials: T
authors.lastname: Thekkekkara
authors.affiliation: Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, UK.
authors.forename: Alistair
authors.initials: A
authors.lastname: Morris
authors.affiliation: University of Leeds Teaching Hospitals, Leeds, UK.
authors.forename: Eric
authors.initials: E
authors.lastname: Finlay
mesh_terms: D000141:Acidosis, Renal Tubular / Q000175:diagnosis; D000927:Anticonvulsants / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003937:Diagnosis, Differential; D005198:Fanconi Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008297:Male; D012640:Seizures / Q000188:drug therapy; D014635:Valproic Acid / Q000009:adverse effects*
chemical_list: D000927:Anticonvulsants; D014635:Valproic Acid
references.citation: Pediatr Nephrol. 2001 Mar;16(3):256-9
references.pmid: 11322374
references.citation: Neuropediatrics. 2011 Jun;42(3):119-21
references.pmid: 21717384
references.citation: Iran Red Crescent Med J. 2011 Nov;13(11):844-5
references.pmid: 22737428
references.citation: Pediatr Nephrol. 2005 Jun;20(6):814-7
references.pmid: 15785938
references.citation: Pediatr Pathol. 1993 Nov-Dec;13(6):863-8
references.pmid: 8108303
references.citation: Eur J Paediatr Neurol. 2002;6(3):165-7
references.pmid: 12363104
references.citation: J Pediatr. 1993 Aug;123(2):320-2
references.pmid: 7688423
references.citation: J Pediatr. 1981 Mar;98(3):503-4
references.pmid: 6782217
references.citation: Pediatr Neurol. 2010 Apr;42(4):287-90
references.pmid: 20304335
references.citation: Pediatr Neurol. 2002 Oct;27(4):318-9
references.pmid: 12435575
references.citation: Nephron. 1996;72(2):328-9
references.pmid: 8684554
references.citation: No To Hattatsu. 2011 May;43(3):233-7
references.pmid: 21638910
references.citation: J Pediatr Neurosci. 2013 May;8(2):135-7
references.pmid: 24082934
references.citation: Am J Kidney Dis. 2003 Feb;41(2):292-309
references.pmid: 12552490
references.citation: Nephrol Dial Transplant. 1995;10(4):543-5
references.pmid: 7624000
references.citation: Clin Biochem. 2013 Oct;46(15):1323-38
references.pmid: 23792104
references.citation: Eur J Pediatr. 1997 Jul;156(7):562-4
references.pmid: 9243242
references.citation: Eur J Pediatr. 2005 Mar;164(3):186-7
references.pmid: 15717181
references.citation: Epilepsia. 2004 Jul;45(7):868-71
references.pmid: 15230715
references.citation: Liver. 2000 Jul;20(4):346-8
references.pmid: 10959815
references.citation: Metab Brain Dis. 2007 Mar;22(1):105-9
references.pmid: 17226098